A Canadian pharmaceutical company is partnering with Harvard University and Brigham and Women’s Hospital to develop an oral drug that blocks the Ebola virus and could be tested on humans as early as this year. James Cunningham, associate professor of medicine at Brigham and Women’s, is the lead researcher on the project.
Trending News
Research Provides Clues to Spleen’s Role in Coronary Artery Disease
Genetic variants may drive visible changes in the spleen that contribute to heart disease
Patient Who Received Pig Kidney Becomes First To Progress to Human Kidney Transplant
Study shows xenotransplantation can serve as a bridge for patients with end-stage kidney disease
Pilots, Flight Attendants Have Greater Risk of Radiation-Related Cancer Death Than Other Professions
Findings support efforts to protect U.S. aircrews from cosmic radiation exposure